Renaissance Technologies
TRIL

Renaissance Technologies’s Trillium Therapeutics Inc. TRIL Stock Holding History

Renaissance Technologies’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-26,000
Closed -$381K – 3874
2020
Q4 		$381K Sell
26,000
-162,257
-86% -$2.34M ﹤0.01% 2940
2020
Q3 		$2.67M Sell
188,257
-167,064
-47% -$1.67M ﹤0.01% 1949
2020
Q2 		$2.87M Buy
+355,321
New +$2.2M ﹤0.01% 1969
2018
Q4 		– Sell
-116,100
Closed -$673K – 3718
2018
Q3 		$673K Sell
116,100
-27,900
-19% -$157K ﹤0.01% 2756
2018
Q2 		$864K Buy
144,000
+102,300
+245% +$652K ﹤0.01% 2656
2018
Q1 		$300K Sell
41,700
-115,322
-73% -$874K ﹤0.01% 3080
2017
Q4 		$1.14M Buy
+157,022
New +$1.3M ﹤0.01% 2613
2016
Q2 		– Sell
-25,478
Closed -$236K – 3578
2016
Q1 		$236K Buy
25,478
+1,380
+6% +$11.6K ﹤0.01% 3045
2015
Q4 		$304K Buy
+24,098
New +$335K ﹤0.01% 2882

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Renaissance Technologies's TRIL Position: Q1 2021 in Review

Renaissance Technologies sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2021, closing a stake of 26,000 shares — an estimated $381K sold.

Renaissance Technologies first reported a position in TRIL in Q4 2015 and held it in 9 quarters. The position peaked at $2.87M in Q2 2020. 125 funds tracked by Wall St. Rank hold TRIL as of Q1 2021.

  • Renaissance Technologies reported no remaining Trillium Therapeutics Inc. position as of Q1 2021 after selling out during the quarter.
  • Renaissance Technologies sold 26,000 Trillium Therapeutics Inc. shares in Q1 2021, an estimated $381K.
  • Renaissance Technologies first reported a position in Trillium Therapeutics Inc. in Q4 2015 and held it in 9 quarters.
  • Renaissance Technologies's Trillium Therapeutics Inc. position peaked at $2.87M in Q2 2020.
  • 125 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2021.

Based on Renaissance Technologies's 13F filing for Q1 2021, filed 13 May 2021.